Preferential Expression of Ca2+-Stimulable Adenylyl Cyclase III in the Supraventricular Area, including Arrhythmogenic Pulmonary Vein of the Rat Heart

Biomolecules. 2022 May 20;12(5):724. doi: 10.3390/biom12050724.

Abstract

Ectopic excitability in pulmonary veins (PVs) is the major cause of atrial fibrillation. We previously reported that the inositol trisphosphate receptor in rat PV cardiomyocytes cooperates with the Na+-Ca2+ exchanger to provoke ectopic automaticity in response to norepinephrine. Here, we focused on adenylyl cyclase (AC) as another effector of norepinephrine stimulation. RT-PCR, immunohistochemistry, and Western blotting revealed that the abundant expression of Ca2+-stimulable AC3 was restricted to the supraventricular area, including the PVs. All the other AC isotypes hardly displayed any region-specific expressions. Immunostaining of isolated cardiomyocytes showed an enriched expression of AC3 along the t-tubules in PV myocytes. The cAMP-dependent response of L-type Ca2+ currents in the PV and LA cells is strengthened by the 0.1 mM intracellular Ca2+ condition, unlike in the ventricular cells. The norepinephrine-induced automaticity of PV cardiomyocytes was reversibly suppressed by 100 µM SQ22536, an adenine-like AC inhibitor. These findings suggest that the specific expression of AC3 along t-tubules may contribute to arrhythmogenic automaticity in rat PV cardiomyocytes.

Keywords: adenylyl cyclase; arrhythmia; atrial fibrillation; pulmonary vein; supraventricular area; t-tubule.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenylyl Cyclases / metabolism
  • Animals
  • Atrial Fibrillation*
  • Myocytes, Cardiac / metabolism
  • Norepinephrine / metabolism
  • Norepinephrine / pharmacology
  • Pulmonary Veins* / metabolism
  • Rats
  • Sodium-Calcium Exchanger / metabolism

Substances

  • Sodium-Calcium Exchanger
  • Adenylyl Cyclases
  • adenylate cyclase 3
  • Norepinephrine

Grants and funding

This research was funded by JSPS KAKENHI (Grant-in-Aid for Young Scientists (B)), grant number 17H15554 and 20K16116 to Y.O., and by collaboration with Ono Pharmaceutical Cooperation, Ltd. (Osaka, Japan).